243 related articles for article (PubMed ID: 30044395)
1. Design Space and QbD Approach for Production of Drug Nanocrystals by Wet Media Milling Techniques.
Peltonen L
Pharmaceutics; 2018 Jul; 10(3):. PubMed ID: 30044395
[TBL] [Abstract][Full Text] [Related]
2. Overcoming the Solubility Barrier of Ibuprofen by the Rational Process Design of a Nanocrystal Formulation.
Ouranidis A; Gkampelis N; Vardaka E; Karagianni A; Tsiptsios D; Nikolakakis I; Kachrimanis K
Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33066680
[TBL] [Abstract][Full Text] [Related]
3. Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product.
Pielenhofer J; Meiser SL; Gogoll K; Ciciliani AM; Denny M; Klak M; Lang BM; Staubach P; Grabbe S; Schild H; Radsak MP; Spahn-Langguth H; Langguth P
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839835
[TBL] [Abstract][Full Text] [Related]
4. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
5. A top-down technique to improve the solubility and bioavailability of aceclofenac: in vitro and in vivo studies.
Narayan R; Pednekar A; Bhuyan D; Gowda C; Koteshwara KB; Nayak UY
Int J Nanomedicine; 2017; 12():4921-4935. PubMed ID: 28744125
[TBL] [Abstract][Full Text] [Related]
6. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®.
Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR
Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209
[TBL] [Abstract][Full Text] [Related]
7. Particle Size Tailoring of Quercetin Nanosuspensions by Wet Media Milling Technique: A Study on Processing and Formulation Parameters.
Cheshmehnoor P; Bolourchian N; Abdollahizad E; Derakhshi A; Dadashzadeh S; Haeri A
Iran J Pharm Res; 2022 Dec; 21(1):e130626. PubMed ID: 36915402
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Study of Intermediate and Critical Quality Attributes for Process Control of High-Shear Wet Granulation Using Multivariate Analysis and The Quality by Design Approach.
Han JK; Shin BS; Choi DH
Pharmaceutics; 2019 Jun; 11(6):. PubMed ID: 31159393
[TBL] [Abstract][Full Text] [Related]
9. Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets.
Badawy SI; Narang AS; LaMarche KR; Subramanian GA; Varia SA; Lin J; Stevens T; Shah PA
J Pharm Sci; 2016 Jan; 105(1):168-81. PubMed ID: 26852852
[TBL] [Abstract][Full Text] [Related]
10. Quality by Design: Concept to Applications.
Swain S; Parhi R; Jena BR; Babu SM
Curr Drug Discov Technol; 2019; 16(3):240-250. PubMed ID: 29521238
[TBL] [Abstract][Full Text] [Related]
11. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach.
Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH
Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667
[TBL] [Abstract][Full Text] [Related]
12. Optimization of the manufacturing process of a complex amphotericin B liposomal formulation using quality by design approach.
Liu H; Rivnay B; Avery K; Myung JH; Kozak D; Landrau N; Nivorozhkin A; Ashraf M; Yoon S
Int J Pharm; 2020 Jul; 585():119473. PubMed ID: 32473373
[TBL] [Abstract][Full Text] [Related]
13. Identification of critical process parameters and its interplay with nanosuspension formulation prepared by top down media milling technology--a QbD perspective.
Ghosh I; Schenck D; Bose S; Liu F; Motto M
Pharm Dev Technol; 2013; 18(3):719-29. PubMed ID: 23061898
[TBL] [Abstract][Full Text] [Related]
14. Nanosuspensions of a poorly soluble investigational molecule ODM-106: Impact of milling bead diameter and stabilizer concentration.
Singhal M; Baumgartner A; Turunen E; van Veen B; Hirvonen J; Peltonen L
Int J Pharm; 2020 Sep; 587():119636. PubMed ID: 32659405
[TBL] [Abstract][Full Text] [Related]
15. Harnessing the potential of machine learning for advancing "Quality by Design" in biomanufacturing.
Walsh I; Myint M; Nguyen-Khuong T; Ho YS; Ng SK; Lakshmanan M
MAbs; 2022; 14(1):2013593. PubMed ID: 35000555
[TBL] [Abstract][Full Text] [Related]
16. Quality by design approach to understand the process of nanosuspension preparation.
Verma S; Lan Y; Gokhale R; Burgess DJ
Int J Pharm; 2009 Jul; 377(1-2):185-98. PubMed ID: 19446617
[TBL] [Abstract][Full Text] [Related]
17. Understanding pharmaceutical quality by design.
Yu LX; Amidon G; Khan MA; Hoag SW; Polli J; Raju GK; Woodcock J
AAPS J; 2014 Jul; 16(4):771-83. PubMed ID: 24854893
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive quality by design approach for stable nanocrystalline drug products.
Jog R; Burgess DJ
Int J Pharm; 2019 Jun; 564():426-460. PubMed ID: 31026489
[TBL] [Abstract][Full Text] [Related]
19. [Application of quality by design in granulation process for ginkgo leaf tablet (Ⅱ)： identification of critical quality attributes].
Xu B; Cui XL; Yang C; Wang X; Shi XY; Qiao YJ
Zhongguo Zhong Yao Za Zhi; 2017 Mar; 42(6):1043-1047. PubMed ID: 29027414
[TBL] [Abstract][Full Text] [Related]
20. QbD Approach towards Robust Design Space for Flutamide/PiperineSelf-Emulsifying Drug Delivery System with Reduced Liver Injury.
Saha M; Sikder P; Saha A; Shah S; Sultana S; Emran T; Banik A; Islam Z; Islam MS; Sharker SM; Reza HM
AAPS PharmSciTech; 2022 Jan; 23(1):62. PubMed ID: 35080685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
